Last reviewed · How we verify
NCT07330713: PRP-NAION
Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study
NA trial testing Autologous Platelet-Rich Plasma (PRP) in Nonarteritic Anterior Ischemic Optic Neuropathy in 31 participants. Completed in 31 May 2024.
31 January 2024
Quick facts
| Lead sponsor | Uludag University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 31 |
| Start date | 1 January 2022 |
| Primary completion | 31 January 2024 |
| Estimated completion | 31 May 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Autologous Platelet-Rich Plasma (PRP)
Conditions studied
- Nonarteritic Anterior Ischemic Optic Neuropathy — all drugs for Nonarteritic Anterior Ischemic Optic Neuropathy →
Sponsor
Uludag University
Who can join
40 and older, any sex, with Nonarteritic Anterior Ischemic Optic Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective randomized clinical study aims to evaluate the efficacy and safety of autologous platelet-rich plasma (PRP) injection in patients with acute non-arteritic anterior ischemic optic neuropathy (NAION). Eligible patients are randomly assigned to receive posterior subtenon PRP injections or to an observation-only control group. The PRP group receives injections at baseline and during follow-up. Comprehensive ophthalmologic evaluations, including best-corrected visual acuity, visual field testing, and retinal nerve fiber layer thickness measurements, are performed at baseline and scheduled follow-up visits. The primary outcomes include changes in visual function and structural optic nerve parameters, as well as the incidence of treatment-related adverse events.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07330713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Autologous Platelet-Rich Plasma (PRP)
Trials testing the same drug.
- NCT07473232 — Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoart · NA · not yet recruiting
- NCT05525572 — Combining Shockwave Therapy and Platelet Rich Plasma to Treat Erectile Dysfunction in Diabetic Men (COCKTAIL-DM) · Phase 1, PHASE2 · terminated
- NCT04967170 — A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus · Phase 1, PHASE2 · active not recruiting
Other Uludag University trials
Trials by the same sponsor.
- NCT07478601 — Effect of Erector Spinae Plane Block on Postoperative Respiratory Function After Laparoscopic Cholecystectomy · NA · not yet recruiting
- NCT07440615 — Lower-Limb Muscle Mass and Cardiovascular and Muscular Performance in Males and Females · NA · not yet recruiting
- NCT07393620 — Predictive Value of aEEG and Cerebral Oxygenation on Neurological Outcomes in Newborns With Mild Hypoxic-Ischemic Enceph · not yet recruiting
- NCT07350018 — Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome · Phase 4 · not yet recruiting
- NCT07365605 — Lower-Limb Muscle Mass and Balance Performance · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07330713 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uludag University
- Last refreshed: 9 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07330713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing